Presentation ACC 2025 Extended Anticoagulant Treatment With A Reduced Versus Full Dose Apixaban In Patients With Cancer-associated Venous Thromboembolism: The API-CAT Study Presenter: Isabelle Mahé March 29, 2025 REGISTER for free or LOG IN to view this content CAD Pharma Endovascular Venous Presentation ACC 2025 Up Next Presentation ACC 2025 Four-Factor Prothrombin Complex Concentrate is Superior to Frozen Plasma in Bleeding Adult Cardiac Surgery Patients with Coagulopathy—Results from a Phase 3, Randomized, Active-Control Study Presenter: Keyvan Karkouti March 29, 2025 More slides + Presentation ACC 2025 Dual Antiplatelet Therapy After PCI According To Bleeding Risk: HOST-BR RCT Presenter: Hyo-Soo Kim March 29, 2025 Presentation ACC 2025 Oral Semaglutide Reduces Cardiovascular Events in People with Type 2 Diabetes with Atherosclerotic Cardiovascular and/or Chronic Kidney Disease: Primary Results From the SOUL Randomized Trial Presenter: Darren K. McGuire March 29, 2025 We Recommend
Presentation ACC 2025 Four-Factor Prothrombin Complex Concentrate is Superior to Frozen Plasma in Bleeding Adult Cardiac Surgery Patients with Coagulopathy—Results from a Phase 3, Randomized, Active-Control Study Presenter: Keyvan Karkouti March 29, 2025
Presentation ACC 2025 Dual Antiplatelet Therapy After PCI According To Bleeding Risk: HOST-BR RCT Presenter: Hyo-Soo Kim March 29, 2025
Presentation ACC 2025 Oral Semaglutide Reduces Cardiovascular Events in People with Type 2 Diabetes with Atherosclerotic Cardiovascular and/or Chronic Kidney Disease: Primary Results From the SOUL Randomized Trial Presenter: Darren K. McGuire March 29, 2025